

**Biocon Limited**

20th KM Hosur Road

Electronics City

Bangalore 560 100, India

T 91 80 2808 2808

F 91 80 2852 3423

CIN : L24234KA1978PLC003417

Date of submission: June 28, 2018

www.biocon.com

To The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON
---	---

Dear Sir/Madam,

Sub: Biocon retains economic interest in Etanercept collaboration with Mylan.**Ref:** Regulations 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the "Company Statement" on the subject matter.

"This is in reference to the announcement by our global partner, Mylan, of a commercialization agreement with Lupin for biosimilar Etanercept for certain markets. Biocon clarifies that it retains its economic interest in this arrangement vis-à-vis Mylan in accordance with its existing collaboration agreement and would benefit from the opportunity to accelerate commercialization of this product." - Company Spokesperson.

We request you to kindly take this to your records as per the requirement of LODR and oblige.

Thanking You,
Yours faithfully
For Biocon Limited

Akhilesh Nand
Chief Compliance Officer

Maka